The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical center payment system proposed rule. The AHA expressed support for several policies in the rule, including direct supervision requirements for certain cardiac rehabilitation services and removing four measures from the Outpatient Quality Reporting program that were recently finalized for removal from the Inpatient Quality Reporting Program, along with the proposal to offer time extensions for data reporting for facilities experiencing an extraordinary circumstance. Provisions the AHA opposed include reducing payment for all drug administration services furnished in off-campus hospital provider-based departments to the “physician fee schedule-equivalent” rate of 40% of the OPPS payment amount, eliminating the inpatient-only list over three years, weakening the ASC Covered Procedures List standard criteria and general exclusion criteria and accelerating the timeline for clawing back funds from CMS' unlawful policy between CY 2018 and 2022 that harmed certain hospitals participating in the 340B Drug Pricing Program.

Related News Articles

Chairperson's File
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Headline
The Centers for Medicare & Medicaid Services Nov. 21 issued a final rule that, among other provisions, increases Medicare hospital outpatient prospective…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…